Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study
This study aimed to prospectively evaluate the association between the appearance and evolution of retinopathy of prematurity (ROP) and selected blood parameters, focusing on platelets count. In total, 157 preterm consecutive babies screened for ROP were included and classified in: ROP necessitating...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/11/11/1120 |
| _version_ | 1797509695190073344 |
|---|---|
| author | Raffaele Parrozzani Giulia Marchione Alberto Fantin Luisa Frizziero Sabrina Salvadori Daniel Nardo Giulia Midena |
| author_facet | Raffaele Parrozzani Giulia Marchione Alberto Fantin Luisa Frizziero Sabrina Salvadori Daniel Nardo Giulia Midena |
| author_sort | Raffaele Parrozzani |
| collection | DOAJ |
| description | This study aimed to prospectively evaluate the association between the appearance and evolution of retinopathy of prematurity (ROP) and selected blood parameters, focusing on platelets count. In total, 157 preterm consecutive babies screened for ROP were included and classified in: ROP necessitating treatment (group ROP1), ROP regressed without therapy (group ROP2) and no ROP (group no-ROP), divided in two phases for each group depending on gestational age. Blood parameters were weekly gathered and referred to postmenstrual age, ROP severity and phase. Platelet count mean values were statistically lower (<i>p</i> < 0.001) during both phases in ROP1 group (179 × 10<sup>9</sup>/L vs. 213 × 10<sup>9</sup>/L in phase 1 and 2, respectively) vs. other groups (ROP2: 286 × 10<sup>9</sup>/L vs. 293 × 10<sup>9</sup>/L; no ROP: 295 × 10<sup>9</sup>/L vs. 313 × 10<sup>9</sup>/L). Platelet count at birth <181 × 10<sup>9</sup> was statistically associated with Type 1 ROP development and evolution (sensibility = 76.47%, 95% confidence interval 60.0–87.6; specificity = 66.12%, 95% confidence interval 57.3–73.9). In ROP 1 group, a platelets count mean value “spike” (392.6 × 109/L) was documented at 36 weeks of corrected gestational age, preceding the need for treatment performed at a median of 38.1 ± 3.2 weeks. Early birth thrombocytopenia is confirmed as a biomarker of development and progression of ROP requiring treatment. The increase of platelets count at 35–37 weeks of corrected gestational age can be considered a possible clinical biomarker anticipating Type 1 ROP progression in preterm infants. |
| first_indexed | 2024-03-10T05:21:23Z |
| format | Article |
| id | doaj.art-17098bfccc0c44f384639fa0a802e101 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T05:21:23Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-17098bfccc0c44f384639fa0a802e1012023-11-22T23:58:13ZengMDPI AGJournal of Personalized Medicine2075-44262021-10-011111112010.3390/jpm11111120Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal StudyRaffaele Parrozzani0Giulia Marchione1Alberto Fantin2Luisa Frizziero3Sabrina Salvadori4Daniel Nardo5Giulia Midena6Department of Neuroscience-Ophthalmology, University of Padova, 35128 Padova, ItalyDepartment of Neuroscience-Ophthalmology, University of Padova, 35128 Padova, ItalyDepartment of Neuroscience-Ophthalmology, University of Padova, 35128 Padova, ItalyDepartment of Neuroscience-Ophthalmology, University of Padova, 35128 Padova, ItalyDepartment of Womens’ and Children Health, University of Padova, 35128 Padova, ItalyDepartment of Womens’ and Children Health, University of Padova, 35128 Padova, ItalyIRCCS, Fondazione Bietti, 00198 Rome, ItalyThis study aimed to prospectively evaluate the association between the appearance and evolution of retinopathy of prematurity (ROP) and selected blood parameters, focusing on platelets count. In total, 157 preterm consecutive babies screened for ROP were included and classified in: ROP necessitating treatment (group ROP1), ROP regressed without therapy (group ROP2) and no ROP (group no-ROP), divided in two phases for each group depending on gestational age. Blood parameters were weekly gathered and referred to postmenstrual age, ROP severity and phase. Platelet count mean values were statistically lower (<i>p</i> < 0.001) during both phases in ROP1 group (179 × 10<sup>9</sup>/L vs. 213 × 10<sup>9</sup>/L in phase 1 and 2, respectively) vs. other groups (ROP2: 286 × 10<sup>9</sup>/L vs. 293 × 10<sup>9</sup>/L; no ROP: 295 × 10<sup>9</sup>/L vs. 313 × 10<sup>9</sup>/L). Platelet count at birth <181 × 10<sup>9</sup> was statistically associated with Type 1 ROP development and evolution (sensibility = 76.47%, 95% confidence interval 60.0–87.6; specificity = 66.12%, 95% confidence interval 57.3–73.9). In ROP 1 group, a platelets count mean value “spike” (392.6 × 109/L) was documented at 36 weeks of corrected gestational age, preceding the need for treatment performed at a median of 38.1 ± 3.2 weeks. Early birth thrombocytopenia is confirmed as a biomarker of development and progression of ROP requiring treatment. The increase of platelets count at 35–37 weeks of corrected gestational age can be considered a possible clinical biomarker anticipating Type 1 ROP progression in preterm infants.https://www.mdpi.com/2075-4426/11/11/1120retinopathy of prematurityinflammationplateletsthrombocytopeniaCRPglycemia |
| spellingShingle | Raffaele Parrozzani Giulia Marchione Alberto Fantin Luisa Frizziero Sabrina Salvadori Daniel Nardo Giulia Midena Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study Journal of Personalized Medicine retinopathy of prematurity inflammation platelets thrombocytopenia CRP glycemia |
| title | Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study |
| title_full | Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study |
| title_fullStr | Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study |
| title_full_unstemmed | Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study |
| title_short | Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study |
| title_sort | thrombocytopenia as type 1 rop biomarker a longitudinal study |
| topic | retinopathy of prematurity inflammation platelets thrombocytopenia CRP glycemia |
| url | https://www.mdpi.com/2075-4426/11/11/1120 |
| work_keys_str_mv | AT raffaeleparrozzani thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT giuliamarchione thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT albertofantin thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT luisafrizziero thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT sabrinasalvadori thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT danielnardo thrombocytopeniaastype1ropbiomarkeralongitudinalstudy AT giuliamidena thrombocytopeniaastype1ropbiomarkeralongitudinalstudy |